Eiger BioPharmaceuticals, Inc.

EIGR

US28249U2042

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 10:13:27 2024-06-26 EDT			5-day change	1st Jan Change
13.2 ^USD	+1.15%		+32.00%	+95.99%

06-21	Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar	RE
05-08	Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.	CI

Eiger Biopharmaceuticals, Inc. Announces Resignation of William G. Kachioff as Chief Financial Officer

May 02, 2024 at 04:32 pm

On April 26, 2024, William G. Kachioff notified Eiger BioPharmaceuticals, Inc. of his resignation as the company's Chief Financial Officer, to be effective April 29, 2024.

Latest news about Eiger BioPharmaceuticals, Inc.

Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar	06-21	RE
Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.	05-07	CI
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug	05-06	MT
Eiger Biopharmaceuticals, Inc. Announces Resignation of William G. Kachioff as Chief Financial Officer	05-02	CI
Eiger Biopharmaceuticals, Inc. Appoints Douglas Staut to Serve as the Company's Chief Restructuring Officer	05-02	CI
Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	04-24	CI
Selection of Successful Bidder Filed by Eiger BioPharmaceuticals, Inc.	04-19	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index	04-09	CI
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
Bidding Procedure Approved for Eiger BioPharmaceuticals, Inc.	04-05	CI
Motion for Joint Administration Approved for Eiger BioPharmaceuticals, Inc.	04-05	CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from S&P TMI Index	04-03	CI
Eiger BioPharmaceuticals, Inc. Announces Resignation of Jeffrey S. Glenn as Member of the Board of Directors	04-03	CI
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup	04-01	DJ
Sector Update: Health Care Stocks Slide Late Afternoon	04-01	MT
Top Midday Decliners	04-01	MT
Sector Update: Health Care	04-01	MT
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection; Shares Fall	04-01	MT
Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	04-01	CI
Motion for Joint Administration Filed by Eiger BioPharmaceuticals, Inc.	04-01	CI
Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy	04-01	CI
Eiger BioPharmaceuticals, Inc. Announces Christine A. Murray Notifies Resignation as Member of Board of Directors, Effective March 15, 2024	03-11	CI
Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024	01-24	CI
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	01-19	MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	01-18	CI

Chart Eiger BioPharmaceuticals, Inc.

Duration

Period

More charts

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its portfolio also includes avexitide, a well-characterized GLP-1 antagonist, as a targeted treatment for two metabolic diseases with high unmet medical needs. The avexitide is a GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, Peginterferon Lambda (lambda) for COVID-19, Avexitide for Congenital Hyperinsulinism (HI) and Avexitide for Post-Bariatric Hypoglycemia (PBH). LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EIGER BIOPHARMACEUTICALS, INC.	+95.99%	19.32M
MODERNA, INC.	+31.14%	52.73B
LONZA GROUP AG	+37.72%	39B
IQVIA HOLDINGS INC.	-9.16%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+26.27%	30.38B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+10.95%	26.08B
UNITED THERAPEUTICS CORPORATION	+44.84%	14.15B
MEDPACE HOLDINGS, INC.	+33.25%	12.6B
BIO-TECHNE CORPORATION	-5.39%	11.51B

Other Biotechnology & Medical Research